 BetterLife Pharma Inc CSE:BETR, OTCQB:BETRF said it has filed a PCT patent application along with a US application for lysergic acid diethylamide LSD derivatives, including 2-bromo-LSD. The applications cover compositions of these derivatives for use in the treatment of a range of neuropsychiatric and neurological conditions, including depression, anxiety, cluster headaches and pain, according to BetterLife. 